Catalyst Event
ABL Bio Inc (298380) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
4/28/2026, 12:00:00 AM
Partner Compass Therapeutics announced on April 27 that the Phase 2/3 trial for biliary tract cancer drug Tovecimig (ABL001) met its Progression-Free Survival (PFS) endpoint but failed to meet the key Overall Survival (OS) endpoint. The news led to a stock price decline of over 20%.
Korean Translation
파트너사 컴퍼스 테라퓨틱스가 4월 27일 발표한 담도암 치료제 토베시미그(ABL001)의 임상 2/3상 결과, 무진행생존기간(PFS) 목표는 충족했으나 주요 지표인 전체생존기간(OS)은 충족하지 못함. 이 소식으로 주가가 20% 이상 급락함.
Related Recent Events
AprilBio Co Ltd (397030) · Other
Final data from the Phase 1b clinical trial of APB-A1 for thyroid eye disease (TED) is scheduled to be presented at the ENDO conference on June 13, 2026. High importance is estimated due to the typical >10% price impact of clinical data, scheduled.
6/13/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Yuhan Corp (000100) · Earnings Release
Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.
4/30/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Earnings Release
Announced Q1 2026 results: Revenue KRW 392.9B (+0.5% YoY), Operating Profit KRW 53.6B (-9.1% YoY), Net Profit KRW 51.1B (+14.4% YoY). The operating profit decline was attributed to a one-off base effect from prior year's clinical trial material supply.
4/30/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
Announced a strategic investment in US biotech 'General Proximity' to secure next-generation 'Induced Proximity' drug development technology, on April 30, 2026.
4/30/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Earnings Release
Announced Q1 2026 earnings with revenue of KRW 447.7 billion (+12.2% YoY) and operating profit of KRW 17.6 billion (+36.9% YoY), beating market expectations.
4/29/2026, 12:00:00 AM